BSD Medical Completes Sale of Fourth BSD-2000 Hyperthermia System to Taiwan Distributor
September 03 2014 - 9:15AM
Business Wire
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD)
(www.BSDMedical.com), a leading provider of medical systems that
treat cancer and benign diseases using heat therapy, announced
today that BSD has completed the sale of its fourth BSD-2000
Hyperthermia Systems (BSD-2000) ordered by its exclusive Taiwan
distributor, Linden Bioscience Co., Ltd (Linden). Linden is a
leading distributor of sophisticated medical devices in Taiwan. The
Company has now sold four BSD-2000 systems since Linden obtained
Taiwan Food and Drug Administration (TFDA) marketing approval in
February 2014.
“We are pleased to have successfully sold four BSD-2000 systems
to Linden in fiscal year 2014,” stated Sam Maravich, Vice President
of International Sales and Marketing of BSD Medical. “Linden
remains very excited about the potential market for hyperthermia
treatment in Taiwan. Linden is making inroads with notable key
opinion leaders in Taiwan, which should help expand awareness of
the clinical benefits of the BSD-2000 throughout Asia,” concluded
Mr. Maravich.
About the BSD-2000 Hyperthermia System
The BSD-2000 – developed and patented exclusively by BSD –
delivers localized therapeutic heating (hyperthermia) by applying
radiofrequency (RF) energy. The BSD-2000 creates a central focusing
of energy that can be electronically focused to target the shape,
size and location of the tumor, thus providing dynamic control of
the heating delivered to the tumor region. The BSD-2000 has
Humanitarian Device Exemption (HDE) marketing approval from the
U.S. Food and Drug Administration (FDA) for use in conjunction with
radiation therapy for the treatment of cervical cancer patients who
are ineligible for chemotherapy. The BSD-2000 also has CE
(Conformité Européenne) Marking approval for the commercial sale in
Europe. CE Marking approval is also recognized in many countries
outside of the EU.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and
services systems to treat cancer and benign diseases using heat
therapy, which is delivered using focused radiofrequency (RF) and
microwave energy. BSD’s product lines include both hyperthermia and
ablation treatment systems. BSD’s hyperthermia cancer treatment
systems, which have been in use for several years in the United
States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other
therapies such as radiation therapy. BSD’s microwave ablation
system has been developed as a stand-alone therapy to employ
precision-guided microwave energy to ablate (destroy) soft tissue.
The Company has developed extensive intellectual property, multiple
products in the market and established distribution in the United
States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States,
Europe and China. For further information visit BSD Medical’s
website at www.BSDMedical.com.
This press release may be deemed to contain forward-looking
statements, which are subject to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Readers are
cautioned that these forward-looking statements are only
predictions and may differ materially from actual future events or
results due to a variety of factors, including, among other things,
the demand for the Company’s products, the ability of the Company
to produce the products to meet the demand, global economic
conditions and uncertainties in the geopolitical environment and
other risk factors set forth in the Company’s most recent reports
on Form 10-K and Form 10-Q. Any forward-looking statements in this
release are based on limited information currently available to the
Company, which is subject to change, and the Company will not
necessarily update the information.
For BSD Medical CorporationTricia Ross,
310-622-8226investor@bsdmc.com